Humana reported second-quarter earnings that topped analysts' estimates, but the health insurer's stock still tumbled about 9% in premarket trading Wednesday after it declined to raise its longer-term profit outlook. The mixed reaction highlights how investors are looking beyond a single quarter's results and focusing on whether insurers can improve profit margins in the years ahead.
What happened
For the quarter ended June 30, Humana posted adjusted earnings of $7.61 per share, above the $7.22 that analysts had expected, according to LSEG data. Revenue jumped 26.2% to $40.87 billion, driven by a 23% increase in Medicare Advantage membership. The company's medical cost ratio — the share of premiums spent on medical care — came in at 91.2%, essentially matching Wall Street's forecast.
Medical costs tracking plan is a positive sign for Humana, as it suggests the insurer is managing expenses in line with its expectations. However, the key disappointment for investors was that Humana kept its 2026 adjusted profit forecast unchanged at at least $9 per share. Many had hoped the company would raise that target after a strong quarter.
Why investors are focused on 2026
Health insurers like Humana operate in a highly regulated environment where profit margins are often thin. The Medicare Advantage business, which is Humana's largest segment, is particularly sensitive to changes in government reimbursement rates and medical cost trends. Investors are keen to see whether Humana can expand its margins over the next few years, especially as the company adds more members.
The decision to hold the 2026 forecast steady suggests that management sees limited near-term upside to profitability, even as membership grows. That caution weighed on the stock, which had rallied ahead of the earnings report on hopes of a more optimistic outlook.
This pattern is not unique to Humana. Other companies have also faced market disappointment when they held steady on full-year outlook despite strong quarterly results. Investors often reward companies that raise guidance, and penalize those that don't, even if the underlying business is performing well.
What it means for investors
For everyday investors, the Humana story is a reminder that earnings season is about more than just beating quarterly estimates. The market is forward-looking, and guidance — especially for future years — can have a bigger impact on stock prices than a single quarter's numbers.
Humana's 2026 profit target of at least $9 per share implies a relatively modest growth trajectory from current earnings levels. If the company can't improve margins, its stock may struggle to gain traction. On the other hand, if medical costs remain well-controlled and Medicare Advantage enrollment continues to grow, Humana could eventually raise that outlook, which would likely boost the stock.
Investors should also consider the broader environment for health insurers. Medicare Advantage plans have faced regulatory headwinds in recent years, including changes to how the government calculates payments. Any shift in policy could affect Humana's profitability. Additionally, medical cost trends are being watched closely across the industry, as higher utilization of healthcare services can pressure margins.
For those looking at the sector, it's worth comparing Humana's performance with peers. Some insurers have been more aggressive in raising guidance, while others have taken a more cautious approach. The key metric to watch is the medical cost ratio, as it directly impacts profitability.
The bottom line
Humana delivered a solid quarter, with earnings and revenue beating expectations and membership growing strongly. But the lack of a bigger outlook raise disappointed investors who were hoping for more. The stock's decline shows that in today's market, guidance matters as much as — if not more than — past performance.
As earnings season continues, investors will be watching for similar dynamics in other sectors. Companies that can beat estimates and raise guidance are likely to be rewarded, while those that hold steady may face selling pressure, even if their results are strong.
